Compounds > imatinib mesylate
Page last updated: 2024-09-03

imatinib mesylate and Osteolysis

imatinib mesylate has been researched along with Osteolysis in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dourthe, LM; Heymann, S; Imperiale, A; Sauer, B; Schlund-Schoettel, E1
Dewar, AL; Fitter, S; Hughes, TP; Vandyke, K; Zannettino, AC1
Beel, K; Brümmendorf, TH; Carmeliet, G; Carmeliet, P; Cauwenberghs, S; Clark, RE; Cools, J; De Keersmaecker, K; De Mol, M; Dewerchin, M; Dias, S; Fragoso, R; Fraisl, P; Hochhaus, A; Holyoake, T; Jonckx, B; Karin, M; Kharabi Masouleh, B; Kleppe, M; Loges, S; Maes, C; Rafii, S; Schenk, T; Schmidt, T; Tjwa, M; Vandenberghe, P; Verfaillie, C; Vinckier, S1
Horny, HP; Jung, AG; Lippert, U; Overbeck, T; Schön, MP; Sotlar, K1

Reviews

1 review(s) available for imatinib mesylate and Osteolysis

ArticleYear
Dysregulation of bone remodeling by imatinib mesylate.
    Blood, 2010, Jan-28, Volume: 115, Issue:4

    Topics: Benzamides; Bone Remodeling; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Osteoclasts; Osteolysis; Piperazines; Protein Kinase Inhibitors; Pyrimidines

2010

Other Studies

3 other study(ies) available for imatinib mesylate and Osteolysis

ArticleYear
[A rare case of bone metastasis from gastro-intestinal stromal tumour: place of radiotherapy].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2014, Volume: 18, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Femoral Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Humerus; Imatinib Mesylate; Ischium; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Osteolysis; Pain Management; Peritoneal Neoplasms; Piperazines; Pubic Bone; Pyrimidines; Stomach Neoplasms

2014
Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.
    Cancer cell, 2011, Jun-14, Volume: 19, Issue:6

    Topics: Animals; Benzamides; Bone Marrow Cells; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; NF-kappa B; Osteolysis; Piperazines; Placenta Growth Factor; Pregnancy Proteins; Pyrimidines

2011
Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis.
    Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:1

    Topics: Absorptiometry, Photon; Administration, Oral; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Middle Aged; Osteolysis; Piperazines; Pyrimidines; Risk Assessment; Severity of Illness Index; Treatment Outcome

2011